DuLac Farmaceutici Expands U.S. Presence with OneLavi Launch and ECRM Participation

DuLac Farmaceutici is accelerating its push into the U.S. market, announcing that its Italian-developed products are now available through OneLavi.com as the company prepares to participate in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, September 14-17 in Palm Beach Gardens, Florida. These developments mark significant steps in DuLac's strategy to expand its presence in the United States.

After establishing consumer demand through Amazon U.S., the Italian pharmaceutical company is adding a new e-commerce channel while preparing to introduce its brand and product portfolio to major U.S. retailers participating at ECRM. DuLac sees the United States as a significant long-term growth market and is building a broader U.S. presence that combines established Amazon demand, expanded e-commerce availability through OneLavi, and direct engagement with retailers and distribution partners.

"ECRM comes at an important time for DuLac because we are making a major commitment to the U.S. market," said Gabriele Bollani, Founder and CEO of DuLac Farmaceutici. "Amazon has demonstrated that American consumers are responding to our products, OneLavi gives us another important U.S. channel, and now we are ready to introduce DuLac to major retailers and build the partnerships that can take our expansion to the next level."

Consumer response on Amazon underscores DuLac's growing presence, with Arnica Gel 98% earning more than 13,000 customer reviews and an average 4.5-star rating, while the company's Dinaven line has received more than 4,000 reviews and maintains a 4.6-star rating. The addition of OneLavi represents the next step in broadening that footprint, giving the company another platform to introduce its Made in Italy portfolio to American consumers.

DuLac's participation at ECRM adds a business-to-business dimension to its U.S. expansion. During the session, DuLac will participate in scheduled meetings with buyers representing major health, specialty, food, drug, and mass retail channels, providing an opportunity to introduce its Italian-developed product portfolio, pharmaceutical heritage, and advanced manufacturing capabilities to potential U.S. retail partners. Among the portfolio DuLac will highlight are its high-concentration Arnica Gel 98% range and the Dinaven and Diosmin lines.

DuLac brings more than 30 years of pharmaceutical industry expertise and pharmacy-channel experience in Italy to its U.S. expansion. The company's product development and manufacturing capabilities include its proprietary Arnica Montana Arricchita™ project, indoor vertical farming, micronized Diosmin MPFF technology, solvent-free Supercritical CO₂ Extraction, and manufacturing under internationally recognized GMP and ISO quality frameworks.

With Amazon already established, OneLavi now live, and scheduled meetings with major retail buyers planned through ECRM, DuLac is moving from initial U.S. market development toward a broader national expansion strategy. The company's goal is to build a diversified U.S. presence across e-commerce, retail, wholesale, and other distribution channels while introducing more American consumers to the DuLac brand and its Italian-developed product portfolio.